Automated Accounts Payable provider Glantus Holdings raises 14M and successfully floats on AIM. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,370.40
Bid: 1,371.20
Ask: 1,371.80
Change: 17.00 (1.26%)
Spread: 0.60 (0.04%)
Open: 1,365.00
High: 1,373.20
Low: 1,360.20
Yest. Close: 1,353.40
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Sanofi And Glaxo Aim For December Start For Phase 3 Of Vaccine Trial

Thu, 3rd Sep 2020 06:37

(Alliance News) - Sanofi SA and Brentford, west London-based GlaxoSmithKline PLC have kicked off the next phase of a trial of their Covid-19 vaccine candidate, the French pharmaceutical firm said on Thursday.

The duo have recruited 400 participants for Phase 1/2 of the study of their adjuvanted recombinant protein-based vaccine candidate.

This part of the study probes the tolerability and effectiveness of the vaccine candidate and the companies expect to report first results in early December. They also aim to begin phase 3 of the trial before the end of the year, should results from the current stage be promising.

In August, GSK said it was in advanced discussions with the European Union to supply up to 300 million doses of the vaccine.

Glaxo said the doses would be manufactured in European countries including France, Belgium, Germany and Italy. It noted that the discussions mark a key milestone in protecting and serving the European population against Covid-19.

The UK, meanwhile, has secured access to six different vaccine candidates, including the Sanofi and GSK venture.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

13 May 21 16:07

CureVac-GSK coronavirus variant vaccine generates good immune response in rats

* CureVac, GSK announced collaboration in Feb* New mRNA specifically targets coronavirus variants* GSK looking for reset after Sanofi, Clover setbacksBy Alistair SmoutLONDON, May 13 (Reuters) - A second-generation COVID-19 vaccine developed by CureV...

13 May 21 15:53

BROKER RATINGS: Just Eat Takeaway and Aston Martin get upgrades

BROKER RATINGS: Just Eat Takeaway and Aston Martin get upgrades

12 May 21 09:34

LONDON BRIEFING: UDG Healthcare accepts GBP2.6 billion takeover offer

LONDON BRIEFING: UDG Healthcare accepts GBP2.6 billion takeover offer

12 May 21 08:11

Tuesday broker round-up

(Sharecast News) - Safestore: Liberum upgrades to buy with a target price of 1,060p.

11 May 21 13:31

BROKER RATINGS: Vodafone on Goldman Sachs' Conviction Buy List

BROKER RATINGS: Vodafone on Goldman Sachs' Conviction Buy List

11 May 21 09:43

CORRECTED-Forestry firm Stora Enso to supply Diageo pulp for paper whisky bottles

(Corrects description of material used in bottle lining in 5th paragraph)By Essi LehtoHELSINKI, May 11 (Reuters) - Finnish forestry firm Stora Enso said on Tuesday it would start supplying pulp for sustainable packaging company Pulpex, a research ...

11 May 21 07:14

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

7 May 21 14:08

CureVac says well on track to request vaccine approval as planned

* Says infections rate within trial population is high* Some doses aimed for production in '21 to be delivered in '22* Trial result will also offer unique view on spread of variantsBy Ludwig BurgerFRANKFURT, May 5 (Reuters) - Germany's CureVac is ...

5 May 21 15:54

UK prosecutor ends investigation into Airbus individuals - sources

By Kirstin RidleyLONDON, May 4 (Reuters) - Britain's Serious Fraud Office (SFO) has ended a criminal investigation into individuals associated with Airbus, the European planemaker that agreed to a record $4.0 billion global settlement 16 months ag...

4 May 21 16:34

GSK's ViiV says HIV drug gets rolling probe from US watchdog

GSK's ViiV says HIV drug gets rolling probe from US watchdog

4 May 21 14:29

Sunday newspaper round-up: GlaxoSmithKline, Rare Earths, Amazon

(Sharecast News) - Top investors in Glaxo Smith Kline are piling pressure on Dame Emma Walmsley after the activist New York hedge fund Elliott Management was revealed to have built a significant stake. Two top-20 investors in the drugs and consumer goods giant said that the chief executive's future was in doubt after four years of disappointing performance. One top-20 investor said there was "no desire to protect her" among institutional shareholders. Another said that Walmsley, 51, should step aside after her plan to break the business in two is carried out and hand over to her lieutenant, Luke Miels. - Sunday Times

2 May 21 12:32

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

30 Apr 21 12:13

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

30 Apr 21 09:43

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

28 Apr 21 17:01

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.